Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India

Hemoglobin

Volumn 36, Issue 5, 2012, Pages 409-420

  Patel, Dilip K ^a   Mashon, Ranjeet S ^b   Patel, Siris ^a   Das, Bhabani S ^c   Purohit, Prasanta ^a   Bishwal, Subasa C ^a  

^a VSS Medical College & Hospital   (India)

^b INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^c INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Fetal hemoglobin (Hb F); Hydroxyurea (HU); Low dose; Maximum tolerated dose (MTD); Painful crises; Sickle cell anemia; Toxicity

Indexed keywords

BILIRUBIN; HEMOGLOBIN F; HYDROXYUREA;

ADOLESCENT; ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; CHILD; CONTROLLED STUDY; DRUG ERUPTION; FEMALE; HUMAN; INDIA; LEUKOCYTE; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; NAIL PIGMENTATION; NEPHROTOXICITY; PAIN; PRESCHOOL CHILD; SCHOOL CHILD; SICKLE CELL ANEMIA; SIDE EFFECT; SKIN PIGMENTATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ACUTE PAIN; ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; FEMALE; FETAL HEMOGLOBIN; HUMANS; HYDROXYUREA; INCIDENCE; INDIA; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866596921     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2012.709897     Document Type: Article

References (30)

1. Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008;148(12):939-955. (Pubitemid 351860826)
2. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects on Hemoglobin F production in patients with sickle cell anemia. Blood. 1992; 79(10):2555-2565.
3. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317-1322.
4. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94 (5):1550-1554. (Pubitemid 29411304)
5. Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program. 2009:62-69.
6. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039-2045. (Pubitemid 38326218)
7. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood. 1996;88(6):1960-1964. (Pubitemid 26307897)
8. Ferster A, Tariri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 2001;97(11):3628-3632.
9. Maier-Redelsperger M, de MontalembertM, Flahault A, et al. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease. Blood. 1998;91(12):4472-4479. (Pubitemid 28270293)
10. Ware RE. Summary of the evidence regarding efficacy of hydroxyurea treatment for sickle cell disease in children and adolescents. Proceedings of the Hydroxyurea Treatment for Sickle Cell Disease, An NIH Consensus Development Conference, held at the William H. Natcher Conference Center, National Institutes of Health, Bethesda, MD, USA on February 25-27 2008. 2008:29-32.
11. Friedrisch JR, Prá D, Maluf SW, et al. DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea. Mutat Res. 2008;649(1-2):213-220. (Pubitemid 350245472)
12. Grigg A. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease. Intern Med J. 2007;37(3):190-192.
13. Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Hematologica. 2008;93(7):988-993. (Pubitemid 351957015)
14. Kar BC. Sickle cell disease in India. J Assoc Phys India. 1991;39(12):954-960
15. Mashon RS, Dash PM, Khalko J, et al. Higher fetal hemoglobin concentration in patients with sickle cell disease in eastern India reduces frequency of painful crisis. Eur J Haematol. 2009;83(4):383-384.
16. Wu DY, Ugozzoli L, Pal BK, Wallace RB. Allele-specific enzymatic amplification of β-globin genomic DNA for diagnosis of sickle cell anemia. Proc Natl Acad Sci USA. 1989;86(8):2757-2760. (Pubitemid 19112620)
17. Old JM, Varawalla NY, Weatherall DJ. Rapid detection and prenatal diagnosis of β-thalassaemia: studies in Indian and Cypriot populations in the UK. Lancet. 1990;33(8719):834-837. (Pubitemid 20311326)
18. Charache S, Terrin ML, Moore RD, et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea. Control Clin Trials. 1995;16(6):432-446. (Pubitemid 26035810)
19. Mukherjee MB, Surve RR, Gangakhedkar RR, Ghosh K, Colah RB, Mohanty D. β-Globin gene cluster haplotypes linked to the βS gene in western India. Hemoglobin. 2004;28(2):157-161. (Pubitemid 38669615)
20. Braga LB, Ferreira AC, Guimarães M, et al. Clinical and laboratory effects of hydroxyurea in children and adolescents with sickle cell anemia: a Portuguese hospital study. Hemoglobin. 2005;29(3):171-180. (Pubitemid 41099684)
21. Italia K, Jain D, Gattani S, et al. Hydroxyurea in sickle cell disease-a study of clinico-pharmacological efficacy in the Indian haplotype. Blood Cells Mol Dis. 2009;42(1):25-31.
22. Noguchi CT, Rodgers GP, Serjeant GR, Schechter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med. 1988;318(2):96-99. (Pubitemid 18029302)
23. Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood. 2002;99(1):10-14. (Pubitemid 34532957)
24. Lebensburger JD, Pestina TI, Ware RE, Boyd KL, Persons DA. Hydroxyurea therapy requires Hb F induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010;95(9):1599-1603.
25. Platt OS. Hydroxyurea for the treatment of sickle cell anaemia. N Eng J Med. 2008;358(13):1362-1369.
26. Orringer EP, Blythe DS, Johnson AE, Phillips G Jr, Dover GJ, Parker JC. Effects of hydroxyurea on Hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anaemia. Blood. 1991;78(1):212-216.
27. Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol. 2000;109(2):322-327. (Pubitemid 30350711)
28. Wiles N, Howard J. Role of hydroxycarbamide in prevention of complications in patients with sickle cell disease. Ther Clin Risk Manag. 2009;5:745-755.
29. Lima CS, Arruda VR, Costa FF, Saad ST. Minimal doses of hydroxyurea for sickle cell disease. Braz J Med Biol Res. 1997; 30(8):933-940. (Pubitemid 127519668)
30. Al-Nood HA, Al-Khawlani MM, Al-Akwa A. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients. Hemoglobin. 2011;35(1):13-21.